Increased serum C-reactive protein levels are associated with shorter survival and development of second cancers in chronic lymphocytic leukemia

References

• Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol. 1999;17:399–408.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–56.
   PubMed Web of Science ®Google Scholar
• Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005;117:104–11.
   PubMed Web of Science ®Google Scholar
• Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48:155–70.
   PubMed Web of Science ®Google Scholar
• Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009;27:2217–24.
   PubMed Web of Science ®Google Scholar
• Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 2007;61:824–33.
   PubMed Web of Science ®Google Scholar
• Wieland A, Kerbl R, Berghold A, Schwinger W, Mann G, Urban C. C-reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease. Med Pediatr Oncol. 2003;41:21–5.
   PubMedGoogle Scholar
• Blackman JD, Cabana VG, Mazzone T. The acute-phase response and associated lipoprotein abnormalities accompanying lymphoma. J Intern Med. 1993;233:201–4.
   PubMed Web of Science ®Google Scholar
• Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF, et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma. 1998;31:351–7.
   PubMed Web of Science ®Google Scholar
• Li YJ, Li ZM, Xia Y, Huang JJ, Huang HQ, Xia ZJ, et al. Serum C-reactive protein (CRP) as a simple and independent prognostic factor in extranodal natural killer/T-cell lymphoma, nasal type. PLoS One. 2013;8:e64158.
   PubMed Web of Science ®Google Scholar
• Cao Y, Shi YX, Chen JO, Tan YT, Cai YC, Luo HY, et al. Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma. Tumour Biol. 2012;33:1039–44.
   PubMed Web of Science ®Google Scholar
• Haase R, Vilser C, Mauz-Korholz C, Hasenclever D, Kluge R, Ruschke K, et al. Evaluation of the prognostic meaning of C-reactive protein (CRP) in children and adolescents with classical Hodgkin's lymphoma (HL). Klin Padiatr. 2012;224:377–81.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Perry C, Braunstein R, Metser U, Goor O, Rogowski O, et al. Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin's lymphoma. Eur J Haematol. 2007;79:150–4.
   PubMed Web of Science ®Google Scholar
• Leonard RC, Cuzick J, MacLennan IC, Vanhegan RI, Mackie PH, McCormick CV. Prognostic factors in non-Hodgkin's lymphoma: the importance of symptomatic stage as an adjunct to the Kiel histopathological classification. Br J Cancer. 1983;47:91–102.
   PubMed Web of Science ®Google Scholar
• Troppan KT, Schlick K, Deutsch A, Melchardt T, Egle A, Stojakovic T, et al. C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. Br J Cancer. 2014;111:55–60.
   PubMed Web of Science ®Google Scholar
• Wood HF, Diamond RD, Craver LF, Pader E, Eister SK. Determination of C-reactive protein in the blood of patients with Hodgkin's disease. Ann Intern Med. 1958;48:823–33.
   PubMed Web of Science ®Google Scholar
• Shenhar-Tsarfaty S, Yayon N, Waiskopf N, Shapira I, Toker S, Zaltser D, et al. Fear and C-reactive protein cosynergize annual pulse increases in healthy adults. Proc Natl Acad Sci USA. 2015;112:E467–71.
   PubMed Web of Science ®Google Scholar
• Rogowski O, Shapira I, Shirom A, Melamed S, Toker S, Berliner S. Heart rate and microinflammation in men: a relevant atherothrombotic link. Heart. 2007;93:940–4.
   PubMed Web of Science ®Google Scholar
• Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev. 2006;15:381–4.
   PubMed Web of Science ®Google Scholar
• Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001;97:256–63.
   PubMed Web of Science ®Google Scholar
• Lai R, O'Brien S, Maushouri T, Rogers A, Kantarjian H, Keating M, et al. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer. 2002;95:1071–5.
   PubMed Web of Science ®Google Scholar
• Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291:585–90.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Caporaso NE, Katki HA, Wong HL, Chatterjee N, Pine SR, et al. C-reactive protein and risk of lung cancer. J Clin Oncol. 2010;28:2719–26.
   PubMed Web of Science ®Google Scholar
• Royle JA, Baade PD, Joske D, Girschik J, Fritschi L. Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. Br J Cancer. 2011;105:1076–81.
   PubMed Web of Science ®Google Scholar
• Manusow D, Weinerman BH. Subsequent neoplasia in chronic lymphocytic leukemia. JAMA. 1975;232:267–9.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol. 2009;27:904–10.
   PubMed Web of Science ®Google Scholar
• Beiggi S, Johnston JB, Seftel MD, Pitz MW, Kumar R, Banerji V, et al. Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study. Br J Cancer. 2013;109:1287–90.
   PubMed Web of Science ®Google Scholar
• Molica S. Second neoplasms in chronic lymphocytic leukemia: incidence and pathogenesis with emphasis on the role of different therapies. Leuk Lymphoma. 2005;46:49–54.
   PubMed Web of Science ®Google Scholar
• Lam CJ, Curtis RE, Dores GM, Engels EA, Caporaso NE, Polliack A, et al. Risk factors for melanoma among survivors of Non-Hodgkin lymphoma. J Clin Oncol. 2015;33:3096–104.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol. 1995;13:2431–48.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet. 2001;357:539–45.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.
   PubMed Web of Science ®Google Scholar
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805–12.
   PubMed Web of Science ®Google Scholar